Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05121519
Other study ID # 21-35115
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 20, 2021
Est. completion date October 20, 2025

Study information

Verified date October 2023
Source University of California, San Francisco
Contact Greg Marcus, MD
Phone 415-608-1565
Email greg.marcus@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This pilot study will evaluate the effect of randomly assigning participants undergoing electrical cardioversion to coffee abstinence or coffee consumption over a 6 month period. This pilot study will provide the first, randomized evaluation of coffee on AF outcomes and will provide important information on whether or not coffee has any effect on AF recurrence.


Description:

The purpose of this study is to assess how abstinence of coffee compared to continued consumption affects recurrent atrial fibrillation (AF) following electrical cardioversion. As one of the most consumed beverages in the world, whether coffee has any effect on health outcomes is of considerable interest to physicians, scientists, and individual consumers. While significant data exist on the potential impact of coffee on many cardiometabolic parameters, there is conflicting data on any role of coffee on AF. Most studies so far have been observational in nature, limiting how much insight there is on the role of coffee on AF. This study proposes to directly compare AF outcomes for patients with AF that abstain from coffee versus those that continue coffee consumption. A total of 200 AF patients undergoing electrical cardioversion will be enrolled in this study (100 per arm), and followed for up to 6 months post cardioversion. Differences in AF recurrence, symptoms, and development/recurrence of other arrhythmias will be compared between the two groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 20, 2025
Est. primary completion date October 20, 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Men and women = 21 years of age - Sustained AF - Planned/scheduled direct current electrical cardioversion - Consumption greater than or equal to one cup of coffee per day sometime in the past 5 years - Willing and able to comply with coffee abstinence or continuation - Life expectancy of at least 1 year - Willing and able to return and comply with scheduled phone follow up visits - Willing and able to provide written informed consent Exclusion Criteria: - Established allergy or adverse reaction to coffee - Stated inability to comply with coffee abstinence or continuation - AF ablation in preceding 6 months or planned in next 6 months - Recent cardiothoracic surgery in preceding 3 months - Cardioversion for atrial flutter rather than AF - Pregnancy or desire to get pregnant within next 6 months. - Current enrollment in an investigation or study of a cardiovascular device or investigational drug that would interfere with this study - Any other criteria, which would make the patient unsuitable to participate in this study as determined by the Principal Investigator (e.g., an uncontrolled drug and/or alcohol addiction)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Consume coffee
Drink coffee regularly (recommend at least 1 cup of coffee per day)
Avoid coffee
Abstain from coffee and other caffeinated beverages

Locations

Country Name City State
United States UCSF Parnassus San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Recurrent AF or AFlutter (Atrial Flutter) The number of patient's with AF and/or AFlutter recurrence following direct current electrical cardioversion will be compared 6 months
Primary Rate of AF or AFlutter Recurrence The time it takes for AF and/or AFlutter recurrence to occur following direct current electrical cardioversion will be compared 6 months
Secondary Severity in AF Symptoms Any change in AF symptoms (measured through the same survey questionnaire taken at 1, 3, 6, and 12 months) following direct current electrical cardioversion will be compared. Severity of symptoms will be measured through a survey questionnaire called "AF severity" asking participants how much their AF symptoms bother them on a scale of 1 to 7, where 7 is most bothersome. 6 months
Secondary Other arrhythmia onset or recurrence Any change in rate of other arrhythmia occurrence determined through routine clinical care will be compared 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A